Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for JIA-associated Uveitis
NCT01385826Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2011
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in uveitis comparing Adalimumab with Placebo (2 arms). Primary endpoint: Proportion of subjects with improvement of uveitis at 2 months. Started Jun 2011; status: completed.
02
Drugs
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT01385826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01385826.